Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2
复制标题
BNT162b2（辉瑞-BioNTech）和 ChAdOx1 nCoV-19（牛津-阿斯利康）疫苗降低 SARS-CoV-2 Delta 变体（B.1.617.2）感染易感性的有效性
DOI：
10.1101/2021.10.12.21264840
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Pattni K
中科院分区：
文献类型：
--
作者：
Pattni K
背景从2021年1月到5月，SARS-CoV-2的阿尔法变种(B.1.1.7)是英国最常见的变种。此后，Delta变体(B.1.617.2)成为主要的变体。英国新冠肺炎疫苗接种计划于2020年12月8日启动。在Delta变体之前，大多数疫苗有效性研究都集中在阿尔法变体上。因此，我们的目标是评估BNT162b2(辉瑞-BioNTech)和ChAdOx1 nCoV-19(牛津-阿斯利康)疫苗在预防有症状和无症状感染方面的有效性。然后，我们构建了一个SIR流行病模型来解释英国柴郡和默西塞德地区的SARS-CoV-2感染数据。结果牛津-阿斯利康疫苗单剂和双剂降低感染易感性的有效率分别为39%(95%可信区间[34，43])和%(95%可信区间[61，67])。对于Pfizer-BioNtech疫苗，单剂和双剂疫苗的有效率分别为20%(95%可信区间[10，28])和84%(95%可信区间[82，86])。结论接种两剂疫苗后，降低SARS-CoV-2感染易感性的疫苗效果明显提高。研究结果还表明，辉瑞-BioNTech的全程治疗提供了预防Delta变体感染的最佳保护。这加强了完成完整课程方案的必要性，以最大限度地保护个人并减少传播。
BackgroundFrom January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta variant, most vaccine effectiveness studies focused on the alpha variant. We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting.MethodsWe used anonymised public health record data linked to infection data (PCR) using the Combined Intelligence for Population Health Action resource. We then constructed an SIR epidemic model to explain SARS-CoV-2 infection data across the Cheshire and Merseyside region of the UK. Vaccines were assumed to be effective after 21 days for 1 dose and 14 days for 2 doses.ResultsWe determined that the effectiveness of the Oxford-AstraZeneca vaccine in reducing susceptibility to infection is 39% (95% credible interval [34, 43]) and 64% (95% credible interval [61, 67]) for a single dose and a double dose respectively. For the Pfizer-BioNTech vaccine, the effectiveness is 20% (95% credible interval [10, 28]) and 84% (95% credible interval [82, 86]) for a single-dose and a double dose respectively.ConclusionVaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission.
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.2807/1560-7917.es.2021.26.24.2100509
发表时间：
2021-06
期刊：
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
影响因子：
--
作者：
Campbell F;Archer B;Laurenson-Schafer H;Jinnai Y;Konings F;Batra N;Pavlin B;Vandemaele K;Van Kerkhove MD;Jombart T;Morgan O;le Polain de Waroux O
通讯作者：
le Polain de Waroux O
利用淋巴细胞表面分子表达对感染性休克患者进行分类
影响因子：
15.1
作者：
J. Monserrat;R. de Pablo;A. Prieto;Eduardo Reyes;Melchor Álvarez
通讯作者：
Melchor Álvarez